Table 1 Patient demographic and clinical characteristics
Variable | N = 97 |
|---|---|
Age (years) at transplantation | 55.6 ± 8.3 (34–70) |
Gender | |
Male | 65 (67) |
Female | 32 (33) |
Underlying liver disease | |
HBV | 45 (46) |
HCV | 38 (39) |
HBV, HCV coinfection | 5 (5) |
Non-B, Non-C | 9 (10) |
MELD score | 10.2 ± 3.8 (6–23) |
Alpha-fetoprotein level (ng/mL) | 15.69 ± 22.82 (3–153) |
Pretransplant treatment | |
Yes | 82 (84) |
Hepatectomy | 5 |
Locoregional therapy (RFA, TACE) | 57 |
Hepatectomy + Locoregional therapy | 20 |
No | 15 (16) |
Tumor downstaging | 5 (5) |
Tumor recurrence | |
Yes | 16 (17) |
No | 81 (83) |